Talawar Therapeutics will use the funds to take its AD (eczema) bispecific, TALA-125, through to Phase IIb proof-of-concept trials.
Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m.
Anixa Biosciences has secured patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results